“In the pharmaceutical drug development community, this is what you dream about.”
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Recent evidence suggests psychedelics may significantly improve addiction treatment outcomes.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.